Free Trial
NASDAQ:PYXS

Pyxis Oncology (PYXS) Stock Price, News & Analysis

Pyxis Oncology logo
$1.12 -0.09 (-7.08%)
Closing price 07/3/2025 03:51 PM Eastern
Extended Trading
$1.12 0.00 (0.00%)
As of 07/3/2025 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pyxis Oncology Stock (NASDAQ:PYXS)

Key Stats

Today's Range
$1.10
$1.24
50-Day Range
$1.04
$1.35
52-Week Range
$0.83
$5.39
Volume
503,969 shs
Average Volume
733,925 shs
Market Capitalization
$69.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Moderate Buy

Company Overview

Pyxis Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
26th Percentile Overall Score

PYXS MarketRank™: 

Pyxis Oncology scored higher than 26% of companies evaluated by MarketBeat, and ranked 2470th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pyxis Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Pyxis Oncology has only been the subject of 1 research reports in the past 90 days.

  • Read more about Pyxis Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for Pyxis Oncology are expected to decrease in the coming year, from ($1.04) to ($1.29) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pyxis Oncology is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pyxis Oncology is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pyxis Oncology has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Pyxis Oncology's valuation and earnings.
  • Percentage of Shares Shorted

    14.04% of the float of Pyxis Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Pyxis Oncology has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Pyxis Oncology has recently decreased by 4.48%, indicating that investor sentiment is improving.
  • Dividend Yield

    Pyxis Oncology does not currently pay a dividend.

  • Dividend Growth

    Pyxis Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.04% of the float of Pyxis Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Pyxis Oncology has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Pyxis Oncology has recently decreased by 4.48%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Pyxis Oncology this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for PYXS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pyxis Oncology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.60% of the stock of Pyxis Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 39.09% of the stock of Pyxis Oncology is held by institutions.

  • Read more about Pyxis Oncology's insider trading history.
Receive PYXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pyxis Oncology and its competitors with MarketBeat's FREE daily newsletter.

PYXS Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Headlines

PYXS Stock Analysis - Frequently Asked Questions

Pyxis Oncology's stock was trading at $1.56 on January 1st, 2025. Since then, PYXS shares have decreased by 28.5% and is now trading at $1.1150.

Pyxis Oncology, Inc. (NASDAQ:PYXS) announced its quarterly earnings data on Thursday, May, 15th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.06.

Pyxis Oncology (PYXS) raised $158 million in an IPO on Friday, October 8th 2021. The company issued 10,500,000 shares at a price of $14.00-$16.00 per share.

Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pyxis Oncology investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Walmart (WMT), Home Depot (HD) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
5/15/2025
Today
7/04/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PYXS
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$13.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+707.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$77.33 million
Pretax Margin
-492.35%

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.03 per share
Price / Book
0.55

Miscellaneous

Free Float
55,382,000
Market Cap
$69.07 million
Optionable
Optionable
Beta
1.13
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:PYXS) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners